市場調査レポート

商品コード

1403494

肺動脈性肺高血圧症の2030年までの市場予測：製品、タイプ、投与経路、エンドユーザー、地域別の世界分析

Pulmonary Arterial Hypertension Market Forecasts to 2030 - Global Analysis By Type, Product, Route of Administration, End User and By Geography

出版日: 2024年01月01日 | 発行: Stratistics Market Research Consulting

| ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,150 650,554円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 822,990円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 995,426円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,175,700円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界の肺動脈性肺高血圧症市場は、2023年に54億米ドルを占め、予測期間中にCAGR 7.4％で成長し、2030年には89億米ドルに達すると予想されています。

肺に血液を供給する動脈の血圧が高いことが肺動脈性肺高血圧症の特徴であり、まれで危険な状態です。呼吸困難や心不全は、この肺動脈の圧力上昇に起因する合併症の一部です。この市場には、PAHの症状をコントロールし緩和することを目的とした様々な治療法があり、最終的な目標は患者の全般的な健康と見通しを向上させることです。

The American Journal of Managed Care誌によると、PAHは米国および欧州で100万人当たり15～50人にみられるまれな疾患です。PAH症例の52.6%は特発性、遺伝性、食欲不振によるものです。通常、PAHは30～60歳の女性に発症します。

危険因子の増加

PAHは多くの場合、結合組織疾患、先天性心疾患、肝疾患などの基礎疾患と関連しています。これらの危険因子の発生率が世界的に上昇するにつれて、PAHの有病率も上昇しています。さらに、座りがちな生活や環境毒素への暴露といったライフスタイルの要因も、PAH患者の増加に寄与しています。高齢者ではPAHと診断されることが多いため、人口の高齢化はさらにリスクを増大させています。このような危険因子による負担の増大は、PAH罹患者数の急増につながり、革新的な治療法、医薬的介入、医療の進歩に対する需要を促進しています。

治療オプションに伴う高コスト

利用可能な治療オプションのコストが高いことが、肺動脈性肺高血圧症市場の大きな障壁となっています。ホスホジエステラーゼ-5阻害薬、エンドセリン受容体拮抗薬、プロスタサイクリン類似物質を含むPAH治療薬のコストは、患者にとってもヘルスケアシステムにとっても法外なものです。PAHの診断と治療は複雑であり、専門的なヘルスケアインフラと知識が必要です。このような経済的、実際的な制約が、効果的なPAH治療を提供することを困難にしており、より容易に入手可能でリーズナブルな価格の治療オプションの必要性を強調しています。

革新的な治療法の開発

肺動脈性肺高血圧症の市場は、新規の治療戦略や重点的な薬剤の開発など、多くの機会を提供しています。技術的・科学的な発展により、PAHの根本的な原因により効果的な新しい治療法を見出すことが可能になった。早期診断の改善と認知度の向上により、より多くの患者を受け入れることができます。

限られた治療選択肢

肺動脈性肺高血圧症の市場は、治療選択肢の少なさと効率的な治療法の創出の困難さによって深刻な脅威にさらされています。PAHはまれで重篤な疾患であるため、この疾患の複雑な病態生理と新規の作用機序の必要性から、新しい治療薬の開発は困難です。しかし、多様で焦点を絞った治療法の欠如は、患者の選択肢を制限し、PAH市場全体の拡大を妨げる可能性があります。

COVID-19の影響：

COVID-19の流行は市場に大きな影響を与えています。封鎖期間中、PAH患者は医療や治療を受けることが困難となった。PAH患者は、ヘルスケアシステムの混乱により、診断や治療開始の遅れを経験しました。さらに、新規のPAH治療薬の研究開発が阻害されたため、可能性のある治療薬のパイプラインにも影響が及びました。PAH市場は、ヘルスケア資源の再配分と経済の不確実性によってさらに緊張しました。パンデミックによる市場力学とPAH管理への長期的な影響は依然として心配であり、これらの問題の解決には継続的な取り組みが必要です。

予測期間中、ホスホジエステラーゼ-5（PDE-5）阻害薬セグメントが最大となる見込み

ホスホジエステラーゼ-5（PDE-5）阻害剤セグメントは予測期間中最大のシェアを獲得しました。タダラフィルやシルデナフィルのようなホスホジエステラーゼ-5（PDE-5）阻害剤は、肺動脈性肺高血圧症市場に不可欠です。これらの薬剤はホスホジエステラーゼ5型酵素を阻害することで機能し、肺動脈を拡張させて血流を改善させる。これらの阻害薬は、PDE-5酵素を特異的に標的とすることによって肺血管の平滑筋細胞を弛緩させ、肺動脈圧を低下させる。PDE-5阻害剤はPAHの治療に広く使用されているため、治療効果を高めるために併用療法が頻繁に行われています。

予測期間中、ジェネリック医薬品のCAGRが最も高くなると予想されます。

ジェネリック医薬品分野は、ブランドPAH治療薬のジェネリック代替品へのアクセスを扱うため、長期にわたって収益性の高い成長を示しています。ジェネリック医薬品は生物学的に同等な代替品であるため、患者により手頃な選択肢を提供します。このセクションは、PAH治療がより利用しやすくなり、より多くの患者が処方された薬剤を購入し服用することを可能にします。このような要素がセグメントの成長を後押ししています。

最もシェアの高い地域

北米の肺動脈性肺高血圧症（PAH）市場が最大のシェアを占めると予想されます。PAHと診断される頻度は増加傾向にあり、その背景には治療法の進歩、診断方法の強化、認知度の向上があります。さらに、北米の広範なヘルスケアシステムと高額な医療費により、最先端の治療法や医薬品へのアクセスが可能になっています。さらに、北米地域におけるPAHの研究開発・普及の主な要因は、製薬会社、研究機関、医療提供者の協力体制です。

CAGRが最も高い地域：

欧州の肺動脈性肺高血圧症市場は、一定期間一貫して成長してきました。治療法の改善、患者や医療従事者の診断に対する意識の高まりが、この地域の市場成長を後押ししています。また、欧州は確立されたヘルスケア・インフラを誇り、こうした先進治療へのアクセスを容易にしています。さらに、同地域の製薬会社、研究機関、ヘルスケア機関の協力体制が、新薬や治療法の導入をもたらし、同地域の成長をさらに後押ししています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Actelion Pharmaceuticals ltd.
Bayer
Eli lilly and company
Gilead Sciences, Inc.
Gsk Plc
Hubei Gedian Humanwell Pharmaceutical Co., Ltd
Johnson & Johnson
Lupin
Pfizer Inc
Sun Pharmaceutical Industries Ltd.
Taizhou Tianrui Chemical Co., Ltd
Teva Pharmaceutical Industries Ltd.
United Therapeutics Corporation
Viatris Inc

図表

List of Tables

Table 1 Global Pulmonary Arterial Hypertension Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
Table 3 Global Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
Table 4 Global Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
Table 5 Global Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
Table 6 Global Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
Table 7 Global Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
Table 8 Global Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
Table 9 Global Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
Table 10 Global Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
Table 11 Global Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
Table 12 Global Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
Table 13 Global Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 14 Global Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
Table 15 Global Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
Table 16 Global Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
Table 17 Global Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
Table 18 Global Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
Table 19 Global Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 20 Global Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 21 Global Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
Table 22 North America Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
Table 23 North America Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
Table 24 North America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
Table 25 North America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
Table 26 North America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
Table 27 North America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
Table 28 North America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
Table 29 North America Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
Table 30 North America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
Table 31 North America Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
Table 32 North America Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
Table 33 North America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
Table 34 North America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 35 North America Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
Table 36 North America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
Table 37 North America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
Table 38 North America Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
Table 39 North America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
Table 40 North America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 41 North America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 42 North America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
Table 43 Europe Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
Table 44 Europe Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
Table 45 Europe Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
Table 46 Europe Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
Table 48 Europe Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
Table 49 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
Table 50 Europe Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
Table 51 Europe Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
Table 52 Europe Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
Table 53 Europe Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
Table 54 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
Table 55 Europe Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 56 Europe Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
Table 57 Europe Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
Table 58 Europe Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
Table 59 Europe Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
Table 60 Europe Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
Table 61 Europe Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 62 Europe Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 63 Europe Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
Table 64 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
Table 65 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
Table 66 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
Table 67 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
Table 68 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
Table 69 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
Table 70 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
Table 71 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
Table 72 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
Table 73 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
Table 74 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
Table 75 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
Table 76 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 77 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
Table 78 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
Table 79 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
Table 80 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
Table 81 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
Table 82 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 83 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 84 Asia Pacific Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
Table 85 South America Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
Table 86 South America Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
Table 88 South America Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
Table 89 South America Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
Table 90 South America Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
Table 91 South America Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
Table 92 South America Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
Table 93 South America Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
Table 94 South America Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
Table 95 South America Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
Table 96 South America Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
Table 97 South America Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 98 South America Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
Table 99 South America Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
Table 100 South America Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
Table 101 South America Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
Table 102 South America Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
Table 103 South America Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 104 South America Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 105 South America Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)
Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Country (2021-2030) ($MN)
Table 106 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Product (2021-2030) ($MN)
Table 108 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Endothelin Receptor Antagonists (2021-2030) ($MN)
Table 109 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Soluble Guanylate Cyclase (sGC) Stimulators (2021-2030) ($MN)
Table 110 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Phosphodiesterase-5 (PDE-5) Inhibitors (2021-2030) ($MN)
Table 111 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Prostacyclin Analogs (2021-2030) ($MN)
Table 112 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Products (2021-2030) ($MN)
Table 113 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Type (2021-2030) ($MN)
Table 114 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Innovative (2021-2030) ($MN)
Table 115 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Generics (2021-2030) ($MN)
Table 116 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Branded (2021-2030) ($MN)
Table 117 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Types (2021-2030) ($MN)
Table 118 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Route of Administration (2021-2030) ($MN)
Table 119 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Oral (2021-2030) ($MN)
Table 120 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Intravenous (2021-2030) ($MN)
Table 121 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other Routes of Administrations (2021-2030) ($MN)
Table 122 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By End User (2021-2030) ($MN)
Table 123 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Hospitals (2021-2030) ($MN)
Table 124 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
Table 125 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Online Pharmacies (2021-2030) ($MN)
Table 126 Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24719

According to Stratistics MRC, the Global Pulmonary Arterial Hypertension Market is accounted for $5.4 billion in 2023 and is expected to reach $8.9 billion by 2030 growing at a CAGR of 7.4% during the forecast period. High blood pressure in the arteries supplying blood to the lungs is a defining feature of pulmonary arterial hypertension, a rare and dangerous condition. Breathing difficulties and heart failure are some of the complications that can result from this elevated pressure in the pulmonary arteries. This market includes a variety of treatments intended to control and alleviate PAH symptoms, with the ultimate goal of enhancing patients' general health and outlook.

According to The American Journal of Managed Care, PAH is a rare disorder found in 15 to 50 persons per million within the United States and Europe. Idiopathic, heritable, and anorexigen-induced PAH make up 52.6% of all PAH cases. Usually, PAH affects women aged between 30 and 60 years.

Market Dynamics:

Driver:

Increasing prevalence of risk factors

PAH is often associated with underlying conditions such as connective tissue diseases, congenital heart defects, and liver disease, among others. As the incidence of these risk factors rises globally, so does the prevalence of PAH. Additionally, lifestyle factors such as sedentary behavior and exposure to environmental toxins contribute to the escalation of PAH cases. The aging population further amplifies the risk, as PAH is more commonly diagnosed in older individuals. This growing burden of risk factors has led to an upsurge in the number of people affected by PAH, driving the demand for innovative treatments, pharmaceutical interventions, and medical advancements.

Restraint:

High costs associated with treatment options

The high cost of available treatment options is a major barrier to the pulmonary arterial hypertension market. The cost of PAH drugs, which include phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogs, can be prohibitive for patients and healthcare systems alike. Optimizing disease management is made more difficult by the complex nature of PAH diagnosis and treatment, which calls for specialized healthcare infrastructure and knowledge. These financial and practical limitations make it difficult to provide effective PAH care and emphasize the need for more readily available and reasonably priced therapeutic options.

Opportunity:

Development of innovative therapeutic approaches

The market for pulmonary arterial hypertension offers a number of opportunities, including the creation of novel treatment strategies and focused medications. Technological and scientific developments have made it possible to find new treatment approaches that are more effective in addressing the underlying causes of PAH. A larger patient pool may result from improved early diagnosis and raised awareness.

Threat:

Limited treatment options

The market for pulmonary arterial hypertension is seriously threatened by the scarcity of treatment options and the difficulty of creating efficient treatments. Because PAH is an uncommon and serious illness, developing new medications is difficult due to the disease's complex pathophysiology and the requirement for novel mechanisms of action. However, the lack of varied and focused treatment options could restrict patient options and impede the PAH market's overall expansion.

COVID-19 Impact:

The COVID-19 pandemic has influentially impacted the market. During lockdowns, patients with PAH had difficulty getting access to medical care and treatments. Patients with PAH experienced delays in diagnosis and treatment initiation due to disruptions in the healthcare system. Additionally, the pipeline of possible medications was impacted by hampered research and development efforts for novel PAH therapies. The PAH market was further strained by reallocations of healthcare resources and economic uncertainties. The pandemic's long-term effects on market dynamics and PAH management are still a worry, and solving these issues will take continued work.

The Phosphodiesterase-5 (PDE-5) Inhibitors segment is expected to be the largest during the forecast period

Phosphodiesterase-5 (PDE-5) Inhibitors segment commanded the largest share over the projected period. Phosphodiesterase-5 (PDE-5) Inhibitors like tadalafil and sildenafil are essential to the market for pulmonary arterial hypertension. These medications function by blocking the phosphodiesterase type 5 enzyme, which causes the pulmonary arteries to dilate and improve blood flow. These inhibitors lower pulmonary arterial pressure by relaxing smooth muscle cells in the pulmonary vessels by specifically targeting the PDE-5 enzyme. PDE-5 inhibitors are frequently used in combination therapy to improve treatment efficacy because they are widely used in the management of PAHs.

The generics segment is expected to have the highest CAGR during the forecast period

The generics segment is showing profitable growth over the period of time as it deals with the accessibility of generic substitutes for name-brand PAH drugs. Generic medications offer patients more affordable options since they are bioequivalent substitutes for their name-brand counterparts. This section helps make PAH therapies more accessible, which makes it possible for a larger group of patients to afford and take their prescribed drugs. These elements are boosting segments growth.

Region with largest share:

The pulmonary arterial hypertension (PAH) market in North America is expected to hold largest share. The frequency of PAH diagnoses is on the rise, which can be attributed to advances in treatment options, enhanced diagnostic methods, and increased awareness. Furthermore, more access to cutting-edge treatments and pharmaceuticals is made possible by North America's extensive healthcare system and high healthcare spending. Moreover, a major factor in the advancement of PAH research, development, and uptake in the North American region has been the cooperative efforts of pharmaceutical companies, research institutes, and healthcare providers.

Region with highest CAGR:

The European market for pulmonary arterial hypertension has grown consistently over a period of time. Improvements in treatment options, growing awareness among patients and healthcare professionals in diagnosis have all fueled market growth in the region. Europe also boasts a well-established healthcare infrastructure, facilitating the accessibility of these advanced treatments. Additionally, the collaborative efforts between pharmaceutical companies, research institutions, and healthcare organizations in the region have resulted in the introduction of novel drugs and therapies, further propelling regional growth.

Key players in the market:

Some of the key players in Pulmonary Arterial Hypertension market include Actelion pharmaceuticals ltd., Bayer, Eli lilly and company, Gilead sciences, inc., Gsk plc , Hubei Gedian Humanwell Pharmaceutical Co., Ltd, Johnson & johnson , Lupin, Pfizer inc, Sun pharmaceutical industries ltd., Taizhou Tianrui Chemical Co., Ltd, Teva pharmaceutical industries ltd., United therapeutics corporation and Viatris inc.

Key Developments:

In December 2023, G+Flas Life Sciences and Bayer AG have signed a letter of intent (LOI) to collaborate on the development of novel Crispr genome-edited tomato varieties that are nutritionally enhanced with vitamin D3. This LOI underscores the shared interest of G+FLAS and Bayer AG in developing tomato seeds that not only meet high commercial standards but also incorporate cutting-edge genetic traits through G+Flas's Crispr genome editing technology.

In October 2023, Viatris Inc., a global healthcare company, announced it has received an offer for the divestiture of substantially all of its Over-the-Counter (OTC) business, and has entered into definitive agreements to divest its Women's Healthcare business. With this announcement the Company has delivered on its commitment to announce agreements on all planned divestitures by the end of 2023 within the Company's previously communicated range, after considering the estimated retained value.

Products Covered:

Endothelin Receptor Antagonists
Soluble Guanylate Cyclase (SGC) Stimulators
Phosphodiesterase-5 (PDE-5) Inhibitors
Prostacyclin Analogs
Other Products

Types Covered:

Innovative
Generics
Branded
Other Types

Route of Administrations Covered:

Oral
Intravenous/ subcutaneous
Other Routes of Administrations

End Users Covered:

Hospitals
Retail Pharmacies
Online Pharmacies
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Pulmonary Arterial Hypertension Market, By Product

5.1 Introduction
5.2 Endothelin Receptor Antagonists
5.3 Soluble Guanylate Cyclase (sGC) Stimulators
5.4 Phosphodiesterase-5 (PDE-5) Inhibitors
5.5 Prostacyclin Analogs
5.6 Other Products

6 Global Pulmonary Arterial Hypertension Market, By Type

6.1 Introduction
6.2 Innovative
6.3 Generics
6.4 Branded
6.5 Other Types

7 Global Pulmonary Arterial Hypertension Market, By Route of Administration

7.1 Introduction
7.2 Oral
7.3 Intravenous
7.4 Other Routes of Administrations

8 Global Pulmonary Arterial Hypertension Market, By End User

8.1 Introduction
8.2 Hospitals
8.3 Retail Pharmacies
8.4 Online Pharmacies
8.5 Other End Users

9 Global Pulmonary Arterial Hypertension Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Actelion Pharmaceuticals ltd.
11.2 Bayer
11.3 Eli lilly and company
11.4 Gilead Sciences, Inc.
11.5 Gsk Plc
11.6 Hubei Gedian Humanwell Pharmaceutical Co., Ltd
11.6 Johnson & Johnson
11.8 Lupin
11.9 Pfizer Inc
11.10 Sun Pharmaceutical Industries Ltd.
11.11 Taizhou Tianrui Chemical Co., Ltd
11.12 Teva Pharmaceutical Industries Ltd.
11.13 United Therapeutics Corporation
11.14 Viatris Inc